- Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
- Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
- Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
- Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
- Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
More ▼
Key statistics
On Tuesday, Atara Biotherapeutics Inc (ATRA:NSQ) closed at 0.69, 247.43% above the 52 week low of 0.1986 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.70 |
---|---|
High | 0.7322 |
Low | 0.69 |
Bid | 0.6978 |
Offer | 0.7391 |
Previous close | 0.7142 |
Average volume | 896.81k |
---|---|
Shares outstanding | 119.36m |
Free float | 111.27m |
P/E (TTM) | -- |
Market cap | 85.25m USD |
EPS (TTM) | -2.61 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 21:00 BST.
More ▼